Zeesta Labs: Continuous Cardiovascular-risk Monitor

Medipex and an independent user researcher collaborated on this project to understand the diabetic patients' market and improve application features to match users' needs.

The clinical need

Cardiovascular disease (CVD) is the main cause of death globally. However, there are no accurate and easy methods to predict CVD risk. Zeesta Labs has developed an AI-powered mobile app to predict CVD risk, primarily for patients with type 2 diabetes. The application monitors digital biomarkers relevant to CVD risk via a smartwatch. The used biomarkers need to be easily and objectively monitored and provide good-quality data to train the proprietary AI model.

Project challenge

Zeesta Labs wanted to explore different routes to the market for their application. Specifically, the company wanted to assess the diabetic patients’ market and needs and to analyse potential digital biomarkers that could be additionally used to feed the model.

How did Medipex help?

Medipex conducted a market analysis, which included the identification of gaps in diabetic and CVD patient management as well as a competitor review outlining Apps and technologies that continuously track biomarkers related to CVD risk.

Medipex collaborated on this project with an independent user researcher who conducted interviews with diabetic patients and health professionals to get insights on how to improve the application features to match the users’ needs.

The project was funded by an RTO grant through Innovate UK Business Growth.

Impact

The complementary pieces of work highlighted the market opportunities and potential barriers to adoption and allowed us to better understand user requirements. It allowed Zeesta Labs to better define their value proposition and skilfully approach the target population. The findings will be used to apply for more funding or to search for a commercial partner.

 

Picture designed by Freepik.